The Cross-Border Biotech Blog

Q3Banner

    In this blog, I am going to comment on the Q3 performance of the group of 60 companies which had share prices of between $0.10 and $0.99 to start 2014. Q3 Results Decliners barely outnumbered advancers by 30 to 29 (Welichem Biotech not included in this analysis) Average and median share price changes […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for October 20th, 2014!   Welcome to your deal review for October 20th, 2014! After a hiatus last week due to Canadian Thanksgiving and our friends to the south celebrating Columbus Day, this week’s post covers deal activity from October 6th 2014. The past two weeks saw notable […]

read more


Q3Banner

    Quiet, no momentum, but Therapeutics – Commercial companies still moved ahead There was renewed interest in the Canadian healthcare sector in the first half of 2014. The institutional interest was focused on the Therapeutics – Commercial group where there were revenues, profitability and tax-inversion potential. In Q1, there was also broader sector momentum […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for October 6th, 2014!   This week saw Concordia Healthcare and Tribute Pharmaceuticals wrap up significant rights acquisition deals for amounts of $90 million and $32 million, respectively.  In addition, Premier Diagnostic Health Services, Xylitol and MedMira each closed financings. For details on these stories and the rest […]

read more


MondayDealTitle

Welcome to your Monday Biotech Deal Review for September 29th, 2014!   The past weeks saw Valeant continue its march on Allergan, this time achieving a settlement on the outstanding Delaware litigation launched by Allergan seeking to delay the takeover.  Allergan shareholders are slated to vote on Dec. 18th on whether or not to oust […]

read more


MondayDealTitle

Welcome to your Monday Biotech Deal Review for September 15th, 2014!   The last few weeks saw a steady rise in activity, with a series of financings being announced as well as closed. The Allergan-Valeant-Pershing Square saga also continues, as Allergan has requested an expedited schedule to obtain a preliminary injunction against Valeant in hopes […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for August 22nd, 2014! Every Monday Steve Zuccarelli reviews the deal activity of Canadian healthcare businesses. In this complementary post series, each week Bloom Burton will highlight the scientific achievements from across the country. This week’s Canada in Science Review includes our first highlighted paper from Saskatoon, home of […]

read more


MondayDealTitle

Welcome to your Monday Biotech Deal Review for August 18th, 2014!   The past week saw Valeant continue its aggressive bid for shares of Allergan, with Valeant extending the expiration of its exchange offer to December 31, 2014.  On the financing side, Supreme Pharmaceuticals has announced a private placement worth up to $5 million in […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for August 15th, 2014! Every Monday Steve Zuccarelli reviews the deal activity of Canadian healthcare businesses. In this complementary post series, each week Bloom Burton will highlight the scientific achievements from across the country. This week’s selection of research articles from across Canada delves into almost all the […]

read more